Novel mutations in CEBPA in korean patients with acute myeloid leukemia with a normal karyotype

Annals of Laboratory Medicine

Volumn 32, Issue 2, 2012, Pages 153-157

  Kim, Sollip ^a   Kim, Dong Hwan ^b   Jang, Jun Ho ^b   Jung, Chul Wbn ^b   Jang, Mi Ae ^b   Ki, Chang Seok ^b   Kim, Jong Won ^b   Kim, Sun Hee ^b   Kim, Hee Jin ^b  

^a Inje University College of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Acute myeloid leukemia; CEBPA; Korea; Mutation; Normal karyotype

Indexed keywords

EID: 84859191073     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2012.32.2.153     Document Type: Article

References (29)

1. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative Incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36. (Pubitemid 35429670)
2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance ofdiagnostic cytogenetics on outcome in AML analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33. (Pubitemid 28452973)
3. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics inacute leukemia. Blood Rev 2004;18:115-36.
4. Estey E and Dormer H. Acute myeloid leukaemia. Lancet 2006;368:1894-907. (Pubitemid 44794525)
5. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003:82-101.
6. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New Engl J Med 2008;358:1909-18. (Pubitemid 351620111)
7. Scholl S, Fricke HJ, Sayer HG, Hoffken K. Clinical implications ofmolecular genetic aberrations in acute myeloid leukemia. J Cancer Res Clin Oncol 2009;135:491-505.
8. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations inacute myeloid leukemia. N Engl J Med 2010;363: 2424-33.
9. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, et al. Acquired mutations inthe genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010;116:2122-6.
10. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011;29:1373-81.
11. Pabst T and Mueller BU. Complexity ofCEBPA deregulation in human acute myeloid leukemia. Clin Cancer Res 2009;15:5303-7.
12. Renneville A, Boissel N, Gachard N, Naguib D, Bastard C, de Botton S, et al. The favorable impact ofCEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009;113:5090-3.
13. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Deiwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009;113:3088-91.
14. Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010;28:570-7.
15. Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011;117:2469-75.
16. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer, 2008.
17. Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009; 100:1343-6.
18. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, et al. Characterization ofCEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005;11:1372-9. (Pubitemid 40326229)
19. Fuchs O, Provaznikova D, Kocova M, Kostečka A, Cvekova P, Neuwirtova R, et al. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Mol Dis 2008;40:401-5.
20. Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, Kuriyama K, et al. Comprehensive analysis ofcooperative gene mutations between class I and class Il in de novo acute myeloid leukemia. Eur J Haematol 2009;83:90-8.
21. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations ofCEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001;27:263-70. (Pubitemid 32201846)
22. Snaddon J, Smith ML, Neat M, Cambal-Parrales M, Dixon-Mclver A, Arch R, et al. Mutations ofCEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 2003;37:72-8. (Pubitemid 36417923)
23. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, van Oosterhoud S, van Putten WL, Valk PJ, et al. Biallelic mutations inthe CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML Hematol J 2003;4:31-40.
24. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH, et al. Mutations inthe gene encoding the transcription factor CCAAT/ enhancer binding protein alpha in myelodysplasia syndromes and acute myeloid leukemias. Blood 2002;99:1332-40. (Pubitemid 34547089)
25. Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA mutations inyounger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624-33. (Pubitemid 41095065)
26. Resende C, Regalo G, Duraes C, Carneiro F, Machado JC. Genetic changes ofCEBPA in cancer: mutations or polymorphisms? J Clin Oncol 2007;25:2493-4; author reply 4-5.
27. Wouters BJ, Louwers I, Valk PJ, Lowenberg B, Delwel R. A recurrent inframe insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profilingbased clustering of AML Blood 2007;109:389-90.
28. Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features. Leuk Res 2011;35:200-7.
29. Lin TC, Hou HA, Chou WC, Ou DL, Yu SL, Tien HF, et al. CEBPA methylation as aprognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia 2011;25:32-40.